基于 ASCENT 研究中 SG 展现的健康相关生活质量(HRQoL)的显著改善结果,2024 年更新的 ESMO 转移性乳腺癌在线指南 v. 1.1 版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)[3]将 SG 治疗 mTNBC 的 ESMO 临床获益量表(ESMO-MCBS)评分,由既往的 4 分调整为最高等级 5 分,这也是目前 mTNBC 二线治...
基于 ASCENT 研究中 SG 展现的健康相关生活质量(HRQoL)的显著改善结果,2024 年更新的 ESMO 转移性乳腺癌在线指南 v. 1.1 版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)[3]将 SG 治疗 mTNBC 的 ESMO 临床获益量表(ESMO-MCBS)评分,由既往的 4 分调整为最高等级 5 分,这也是目前 mTNBC 二线治...
Cancer Network, Inc., All Rights Reserved. NCCN Guidelines Version 4.2022 NCCN Guidelines Index Table of Contents Breast Cancer Discussion *William J. Gradishar, MD/Chair ‡ † Sharon H. Giordano, MD, MPH † Lori J. Pierce, MD § Robert H. Lurie Comprehensive Cancer The University of ...
“In addition to the 3.6 mg monthly dose, I am pleased to see that NCCN recognizes the role of goserelin 10.8 mg every 12 weeks as an option for premenopausal women with hormone receptor positive (HR+) breast cancer, ” said Virginia Kaklamani, MD, ...
Personalized oncology also demands that clinicians present guideline information to each patient in a thorough, comprehendible and unbiased manner. Finally, the patient’s ability to process that information for shared decision-making about whether an intervention is consistent with their personal ...
Suicide gene therapy has become an effective therapy for breast cancer, and ultrasound targeted microbubble destruction (UTMD) has become a popular topic in the gene therapy field. In this study, MCF-7 cells with the KDR promoter and LSl74T cells without the KDR promoter were transfected with...
2019年09月06号,NCCN Guideline_Breast Cancer进行了更新,更新后版本为Version 3.2019 02.Johnson阅读的目的: 虽然本人致力于开发肿瘤免疫治疗疗法,然而,肿瘤往往存在多种免疫耐受机制,想要逆转免疫耐受必须要联合治疗——除了耳熟能详的PD-1,还可以选择在肿瘤免疫耐受状态形成过程起主导作用的突变基因(靶向治疗)。因...
provided for free to Chinese medical professions with the support of the unrestrictive educational grant of Sanofi-Aventis (China) Investment Co., Ltd. which exerts no influence to the formation of the Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Breast Cancer Guideline 2011. ...
EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024 EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment ...
Now, in terms of where I would use it, if I have a patient with bona fide germline BRCA mutation, I would feel comfortable using it as a first-line or definitely as a second-line agent, particularly for triple-negative breast cancer. It’s a difficult discussion in ER-positive ...